Merck's CAPVAXIVE vaccine receives FDA approval, entitling Ligand Pharmaceuticals to a $2 million milestone payment and royalty on sales. Takeda's soticlestat shows mixed results in Phase 3 trials for Dravet Syndrome and Lennox-Gastaut Syndrome, with Ligand acquiring a portion of royalties and milestones from Ovid Therapeutics.